Ownership signal 2 signals
Large-stake signal

Form

SCHEDULE 13D/A

Active or control-oriented beneficial ownership filing.

Ownership

0%

Beneficial ownership of this reported class.

Shares

4 shares

Shares beneficially owned as disclosed.

Event date

15 Aug 2025

Date tied to the ownership event or amendment.

Accepted by SEC

19 Aug 2025

EDGAR acceptance date.

How to read this large-stake filing
  • Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
  • Compare this filing with the holder history and issuer page before treating the percentage as a current position.
  • Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
Subject security 1 source field
Symbol
ADAP
Source evidence 4 source fields
Form type
SCHEDULE 13D/A
Accepted by SEC
19 Aug 2025, 18:53:37 UTC
Event date
15 Aug 2025
SEC filing
View on sec.gov

Key filing fact

New Enterprise Associates 14, L.P. disclosed 0% ownership in Adaptimmune Therapeutics Plc Ordinary Shares, (pound).001 par value per share (ADAP) on 15 Aug 2025.

Key facts

  • New Enterprise Associates 14, L.P. filed SCHEDULE 13D/A for Adaptimmune Therapeutics Plc Ordinary Shares, (pound).001 par value per share (ADAP).
  • Disclosed ownership: 0%.
  • Date of event: 15 Aug 2025.

Change

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 19 Aug 2025, 18:53.

Research use

  • This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
  • Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting persons

Disclosed reporting parties (11)

Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares owned Sole voting power Shared voting power Signature Title CIK
New Enterprise Associates 14, L.P. 0% 4 0 4 /s/ Zachary Bambach Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer 0001544328
NEA Partners 14, L.P. 0% 4 0 4 /s/ Zachary Bambach Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer 0001551531
NEA 14 GP, LTD 0% 4 0 4 /s/ Zachary Bambach Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer 0001551532
New Enterprise Associates 16, L.P. 0% 4 0 4 /s/ Zachary Bambach Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer 0001694560
NEA Partners 16, L.P. 0% 4 0 4 /s/ Zachary Bambach Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer 0001712881
NEA 16 GP, LLC 0% 4 0 4 /s/ Zachary Bambach Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer 0001712882
Forest Baskett 0% 4 0 4 /s/ Zachary Bambach Zachary Bambach as attorney-in-fact for Forest Baskett 0001277631
Anthony A. Florence, Jr. 0% 4 0 4 /s/ Zachary Bambach Zachary Bambach as attorney-in-fact for Anthony A. Florence, Jr. 0001559827
Patrick J. Kerins 0% 4 0 4 /s/ Zachary Bambach Zachary Bambach as attorney-in-fact for Patrick J. Kerins 0001235112
Mohamad H. Makhzoumi 0% 4 0 4 /s/ Zachary Bambach Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi 0001630226
Scott D. Sandell 0% 4 0 4 /s/ Zachary Bambach Zachary Bambach as attorney-in-fact for Scott D.Sandell 0001237289
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .